PSE
20.4.2021 13:49:12 CEST | Business Wire | Press release
Process Systems Enterprise (PSE), a Siemens business, today released its rebranded gPROMS Process advanced process modelling environment.
Formerly known as gPROMS ProcessBuilder, gPROMS Process 2.0 is the first major release since PSE was acquired by Siemens. Eckard Eberle, CEO of Siemens Digital Industries Process Automation division, says “the significantly enhanced capabilities and functionality you see in this release reflect the substantial investment Siemens is making into product development within PSE to provide the process industries with a new generation of digital tools.”
Costas Pantelides, PSE CEO and architect of the gPROMS platform, says “The name change signifies a break with the past. Until now, ProcessBuilder has been an environment for sophisticated users who are typically running high-value, complex optimizations. This is the first release in a major, multi-year development programme that will bring the cutting-edge capabilities of the gPROMS platform to users across process organisations”.
The release contains significant new model library content, including a new polyolefins library to support online nonlinear control applications for polymers such as LDPE and HDPE; an advanced model library for electrochemical reactors to support the optimization of clean energy and hydrogen systems; a data-driven model library for hybrid modelling combining data-driven elements with first-principles models; new batch distillation and decanter models for specialty chemicals; enhancements to the multistream heat exchanger for LNG and cryogenic process optimization and to PSE’s industry-leading catalytic reactors model library; and a unique new cyclic steady-state solver to speed up modelling of adsorption processes.
gPROMS Process includes an all-new integral gPROMS Properties package containing all industry-standard thermodynamic models plus PSE’s industry-leading SAFT-γ Mie, which allows accurate prediction of physical properties and phase behaviour with minimal experimental data. “We aim to provide the world’s leading materials modelling capability within a process simulator”, says Pantelides. “covering strongly associating, polymer and active pharmaceutical ingredient systems within a single properties package”.
gPROMS Process also supports the automatic generation of fast-solving surrogate models, technology already extensively proven on large-scale, multi-site optimization projects. A new interface to Siemens’ STAR-CCM+ simplifies combining process and CFD hydrodynamic models for detailed equipment design. Support for the gPROMS Web Applications Platform (gWAP) makes it easy to supply models to users across the organisation via web interfaces.
gPROMS Process is unique among process simulation tools in that it was designed from the start to support the entire process lifecycle, from R&D to operations. Its comprehensive digital design capability makes it possible to explore the process decision space rapidly and effectively, and determine optimal values for multiple design variables simultaneously to arrive at truly optimized designs in the minimum time. gPROMS Process models can be exported for implementation online within the gPROMS Digital Applications Platform (gDAP), for real-time monitoring, soft-sensing and real-time optimization applications coupled with plant data.
About: www.psenterprise.com/news/pressroom
View source version on businesswire.com: https://www.businesswire.com/news/home/20210420005688/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 22:22:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom